NMTcNP-8 is under clinical development by NeoMatrix Therapeutics and currently in Phase I for Burns. According to GlobalData, Phase I drugs for Burns have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NMTcNP-8’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NMTcNP-8 overview
NMTcNP-8 is under development for the prevention and treatment of burns. It is a bioactive peptide. It is administered by topical and intravenous route. It targets platelet-derived growth factor-BB (PDGF-BB) and transforming growth factor-beta 1.
NeoMatrix Therapeutics overview
NeoMatrix Therapeutics is a clinical-stage company that develops novel therapeutic agents for the treatment of serious burn injuries and focus on the treatment of severe burns. NeoMatrix Therapeutics is headquartered in Suffolk County, New York, the US.
For a complete picture of NMTcNP-8’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
